Patents Examined by Shengjun Wang
  • Patent number: 11944602
    Abstract: The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: April 2, 2024
    Assignee: NOVARTIS AG
    Inventors: Eric Legangneux, Alexandros Sagkriotis, Pierre Jordaan, Florine Polus, Alan John Camm, Shibadas Biswal, Parasar Pal, Uday Kiran Veldandi, Atul Keshav Pawar, Vassilios Aslanis, Kasra Shakeri-Nejad
  • Patent number: 11939303
    Abstract: The present invention relates to 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives and derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol as new compounds. The subject of the invention is the medical use of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives and the medical use of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol derivatives. The subject of the invention is the use of new compounds as an agent with the properties of a steroid sulfatase inhibitor and/or an estrogen receptor modulator. The present invention relates to the medical use of novel compounds for use as an antimicrobial medicament and/or estrogen receptor modulator. In particular, 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives are for use as medicament in cancer therapy.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: March 26, 2024
    Assignee: Politechnika Gdanska
    Inventors: Sebastian Demkowicz, Mateusz Dasko, Janusz Rachon
  • Patent number: 11912717
    Abstract: The present invention relates to a crystal form I of tenvermectin B, which can be characterized by X-ray powder diffraction (XRPD) pattern, Infrared (IR) absorption spectrum, Differential scanning calorimetry (DSC) thermogram and the like. Meanwhile, the present invention also relates to a method for preparing the crystal form I of tenvermectin B and a use thereof.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: February 27, 2024
    Assignee: Shenzhen Tenver Biopharm Co., Ltd.
    Inventors: Jidong Wang, Jiansong Li, Hui Zhang, Lingjian Zhang, Jun Huang
  • Patent number: 11912695
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: February 27, 2024
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
  • Patent number: 11903917
    Abstract: The present invention relates to PD-0184264 for use in a method for the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza vims infection or a viral or bacterial infection alone. Also provided are compositions comprising such inhibitors for use in the prophylaxis and/or treatment of a co-infection comprising a bacterial infection and an influenza virus infection or a bacterial or viral infection alone.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: February 20, 2024
    Assignee: ATRIVA THERAPEUTICS GMBH
    Inventors: Stephan Ludwig, Oliver Planz
  • Patent number: 11890289
    Abstract: This invention provides for a method of treating secondary adrenal insufficiency by co-administrating therapeutically effective amounts of a glucocorticoid and a glucocorticoid receptor antagonist to the patient in need thereof. In some embodiments, the method includes the proviso that the patient not be otherwise in need of treatment with a glucocorticoid and a glucocorticoid receptor antagonist. The treatment method can increase the patient's morning or basal cortisol level to at least about 12 ?g/dL or a standard control level, and in turn, expedite significantly the recovery of the HPA axis. The method provided herein can improve health outcomes and life-threatening complications associated with secondary adrenal insufficiency.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: February 6, 2024
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Andreas G. Moraitis, Pejman Cohan, Joseph K. Belanoff
  • Patent number: 11883411
    Abstract: The present disclosure belongs to the technical field of African swine fever (ASF) treatment, in particular to use of a compound aprepitant in prevention or treatment of the ASF. In the present disclosure, it is found that the compound aprepitant can significantly inhibit replication of an African swine fever virus (ASFV); in addition, it is found that the aprepitant inhibits transcription and protein expression of D1133L, and reduces transcription and protein expression levels of p30 and p72, preventing virus invasion on host cells. Therefore, the compound aprepitant can be used to inhibit early and late infection of the ASFV. Accordingly, the compound aprepitant can be used to prevent or treat the ASF.
    Type: Grant
    Filed: August 25, 2022
    Date of Patent: January 30, 2024
    Assignee: LANZHOU VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
    Inventors: Keshan Zhang, Haixue Zheng, Huimei Cui, Bo Yang, Hong Tian, Zixiang Zhu, Tao Feng, Fan Yang, Weijun Cao, Xusheng Ma, Yi Ru, Jianhong Guo, Xiangtao Liu
  • Patent number: 11883415
    Abstract: The present disclosure provides high concentration formulations of cortexolone-17?-propionate suitable for treating alopecia.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: January 30, 2024
    Assignee: Cassiopea S.P.A.
    Inventor: Luigi Maria Longo
  • Patent number: 11865179
    Abstract: This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.
    Type: Grant
    Filed: June 15, 2021
    Date of Patent: January 9, 2024
    Assignee: TherapeuticsMD, Inc.
    Inventors: Janice Cacace, Peter H. R. Persicaner, Thorsteinn Thorsteinsson, Frederick Sancilio, Julia Amadio, Brian Bernick, Neda Irani
  • Patent number: 11866425
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: January 9, 2024
    Assignee: Pfizer Inc.
    Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
  • Patent number: 11857537
    Abstract: The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort.
    Type: Grant
    Filed: March 23, 2021
    Date of Patent: January 2, 2024
    Assignee: JENIVISION INC.
    Inventors: David Frederick Woodward, Weizhen Wang
  • Patent number: 11850252
    Abstract: The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: December 26, 2023
    Assignee: DR. FALK PHARMA GMBH
    Inventors: Markus Pröls, Roland Greinwald, Michael Trauner, Peter Fickert
  • Patent number: 11844803
    Abstract: The present invention addresses the problem of providing a pharmaceutical composition for treatment of a variety of conditions accompanied by renal dysfunction. Renal dysfunction is improved by a pharmaceutical composition that comprises an optical isomer of a 1,4-benzothiazepine-1-oxide derivative represented by general formula [II] wherein, R represents a hydrogen atom or a hydroxyl group, and “*” indicates being an optical isomer. or a pharmacologically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: December 19, 2023
    Assignees: AETAS PHARMA CO., LTD.
    Inventor: Noboru Kaneko
  • Patent number: 11840530
    Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: December 12, 2023
    Assignee: AskAt Inc.
    Inventors: Yukinori Take, Shinichi Koizumi, Takako Okumura, Kazuhiko Nonomura
  • Patent number: 11839610
    Abstract: A method for inhibiting infection of SARS-CoV-2 in a subject is provided, comprising administering an effective amount of plant extract, wherein the plant extract comprises an alcohol extract of the herbal of Menispermaceae, wherein the herbal of Menispermaceae is Stephania cepharantha or Stephania tetrandra.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: December 12, 2023
    Assignees: CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY, CHANG GUNG UNIVERSITY
    Inventors: Tsong-Long Hwang, Yu-Li Chen, Yu-Chia Chang
  • Patent number: 11833140
    Abstract: Provided are methods for treating, ameliorating, reversing and/or preventing a Helicobacter pylori (H. pylori) infection in an individual in need thereof, comprising: administering to the individual in need thereof a therapeutic combination comprising: (a) a composition comprising or consisting of: vonoprazan or a vonoprazan fumarate, or a 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine monofumarate, or a 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methyl-methanamine fumarate), optionally TAKECAB™; and (b) an antimicrobial or antibiotic drug or composition.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: December 5, 2023
    Assignee: CENTRE FOR DIGESTIVE DISEASES
    Inventor: Thomas Julius Borody
  • Patent number: 11826357
    Abstract: Disclosed herein are compounds of formula I and salts thereof. Also disclosed are compositions comprising compounds of formula I and methods using compounds of formula I.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: November 28, 2023
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Edmond J. LaVoie, Ajit Parhi, Yi Yuan, Yongzheng Zhang, Yangsheng Sun
  • Patent number: 11827630
    Abstract: Provided are novel crystalline forms of Lanifibranor (Referred to as “Compound I”) and preparation methods thereof, pharmaceutical compositions containing the crystalline forms, and uses of the crystalline forms for preparing pan-PPAR agonists drugs and drugs for treating NASH. Compared with prior arts, the provided crystalline forms of Compound I have one or more improved properties, which solve the problems of the prior art and is of great value to the optimization and development of the drugs.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: November 28, 2023
    Assignee: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.
    Inventors: Minhua Chen, Hongyan Zhu
  • Patent number: 11814368
    Abstract: The present invention provides a compound exhibiting coronavirus 3 CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same. A compound represented by Formula: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: November 14, 2023
    Assignees: SHIONOGI & CO., LTD., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Yuki Tachibana, Shota Uehara, Yuto Unoh, Kenji Nakahara, Yoshiyuki Taoda, Yukiko Yamatsu, Shigeru Ando, Michihito Sasaki
  • Patent number: 11814366
    Abstract: The present invention relates to compounds of formula (I), their use as medicaments, in particular as broad spectrum antiviral agents, their combination with a further antiviral agent and relative pharmaceutical compositions. In particular, the compounds of the invention are useful in the treatment of a disease caused by an enveloped virus.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: November 14, 2023
    Assignee: UNIVERSITA DEGLI STUDI DI SIENA
    Inventors: Maurizio Botta, Filippo Canducci, Valeria Cagno, David Lembo, Cristina Tintori, Annalaura Brai, Nastasja Palombi